Livanova usa, inc.Submits this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation, based on information that livanova has obtained, but may not have been able to investigate or verify prior to the date the report was required by the fda.This report does not constitute an admission, or a conclusion by fda or anyone else, that the device, livanova, or livanova's employees caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any "defects¿ or "malfunctions¿.These words are incorporated into the fda 3500a medwatch form by the fda, and livanova objects to their use.
|
Additional information received noting that the patient underwent a sleep study and she experienced a decrease in o2 saturation.The patient also reports that her seizure frequency is less, but it seems that when she has a breakthrough seizure, they are more intense, but she is able to recover more quickly.The physician just notes that the patient has anxiety (not alleged against the vns) but never had hypoxia triggered by anxiety.The physician would like to stay on the current medication and vns settings until theyre able to resolve the hypoxia issue, no additional intervention was noted.
|